Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.

Østoft SH

Danish medical journal1 Sept 2015Cited by 4 (Europe PMC)

PMID26324089PepBankPUB-26324089

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with HNF1A-diabetes, liraglutide lowered fasting plasma glucose, as did glimepiride, over 6 weeks.
In plain wordsIn patients with HNF1A-diabetes, liraglutide lowered fasting blood sugar over 6 weeks, as glimepiride did.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
In the prospective intervention trial a glucose lowering effect on fasting plasma glucose (FPG) was demonstrated with both treatments without significant difference between the treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408901
02HumanRandomized controlled trialEfficacy outcome
In patients with HNF1A-diabetes, the postprandial plasma glucose responses were lower with liraglutide than at baseline, as with glimepiride.
In plain wordsIn patients with HNF1A-diabetes, blood sugar after meals was lower with liraglutide than at baseline, as with glimepiride.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma glucose response
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
The postprandial plasma glucose responses were also lower with both glimepiride and liraglutide compared to baseline without significant difference between treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408902
03HumanRandomized controlled trialEfficacy outcome
In patients with HNF1A-diabetes, fasting and postprandial glucose lowering with liraglutide did not differ significantly from glimepiride.
In plain wordsIn patients with HNF1A-diabetes, liraglutide and glimepiride lowered blood sugar by amounts that did not differ significantly.
Peptide
Liraglutide
Outcome
No significant changeGlucose lowering, liraglutide versus glimepiride
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
In the prospective intervention trial a glucose lowering effect on fasting plasma glucose (FPG) was demonstrated with both treatments without significant difference between the treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
The postprandial plasma glucose responses were also lower with both glimepiride and liraglutide compared to baseline without significant difference between treatments.
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408903
04HumanRandomized controlled trialSafety outcome
In patients with HNF1A-diabetes, hypoglycaemic events occurred once during liraglutide treatment and 18 times during glimepiride treatment.
In plain wordsIn patients with HNF1A-diabetes, low blood sugar events were much rarer with liraglutide than with glimepiride.
Peptide
Liraglutide
Outcome
DecreaseHypoglycaemic events
Study
n = 16
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
Hypoglycaemic events (plasma glucose ≤ 3.9 mM) occurred 18 times during glimepiride treatment and once during liraglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408904
05HumanRandomized controlled trialMechanism
In patients with HNF1A-diabetes, insulin responses did not differ between liraglutide and glimepiride.
In plain wordsIn patients with HNF1A-diabetes, insulin responses did not differ between liraglutide and glimepiride.
Peptide
Liraglutide
Outcome
No significant changeInsulin response
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
No differences between treatments were demonstrated according to insulin and glucagon responses and gastric emptying, and counter-regulatory responses were preserved during both treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408905
06HumanRandomized controlled trialMechanism
In patients with HNF1A-diabetes, glucagon responses did not differ between liraglutide and glimepiride.
In plain wordsIn patients with HNF1A-diabetes, glucagon responses did not differ between liraglutide and glimepiride.
Peptide
Liraglutide
Outcome
No significant changeGlucagon response
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
No differences between treatments were demonstrated according to insulin and glucagon responses and gastric emptying, and counter-regulatory responses were preserved during both treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408906
07HumanRandomized controlled trialMechanism
In patients with HNF1A-diabetes, gastric emptying did not differ between liraglutide and glimepiride.
In plain wordsIn patients with HNF1A-diabetes, gastric emptying did not differ between liraglutide and glimepiride.
Peptide
Liraglutide
Outcome
No significant changeGastric emptying
Study
n = 16
Comparator
Glimepiride
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
No differences between treatments were demonstrated according to insulin and glucagon responses and gastric emptying, and counter-regulatory responses were preserved during both treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408907
08HumanRandomized controlled trialSafety outcome
In patients with HNF1A-diabetes, counter-regulatory responses were preserved during liraglutide treatment, as during glimepiride.
In plain wordsIn patients with HNF1A-diabetes, the body's counter-regulatory responses to low blood sugar were preserved during liraglutide treatment.
Peptide
Liraglutide
Outcome
No significant changeCounter-regulatory responses
Study
n = 16
Comparator
Glimepiride
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
No differences between treatments were demonstrated according to insulin and glucagon responses and gastric emptying, and counter-regulatory responses were preserved during both treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408908
09HumanRandomized controlled trialEfficacy outcome
In patients with HNF1A-diabetes, liraglutide had no effect on fructosamine.
In plain wordsIn patients with HNF1A-diabetes, liraglutide had no effect on fructosamine over 6 weeks.
Peptide
Liraglutide
Outcome
No significant changeFructosamine
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
No effect of either treatment was seen on fructosamine or HbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408909
10HumanRandomized controlled trialEfficacy outcome
In patients with HNF1A-diabetes, liraglutide had no effect on HbA1c.
In plain wordsIn patients with HNF1A-diabetes, liraglutide had no effect on HbA1c over 6 weeks.
Peptide
Liraglutide
Outcome
No significant changeHbA1c
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (human).
Source sentences
Summary
No effect of either treatment was seen on fructosamine or HbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
In Study III we conducted a randomised, double-blind, crossover trial investigating the glucose lowering effect and risk of hypoglycaemia during 6 weeks of treatment with the GLP-1RA, liraglutide compared to the SU, glimepiride in 16 patients with HNF1A-diabetes.
Report a problemFND-2632408910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.